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Introduction: Cardioembolic stroke (CE) has poor outcomes and high recurrence
rates. A low ankle-brachial index (ABI <0.9) is associated with atrial fibrillation (AF) and
poor stroke outcomes. We investigated whether a low ABI is associated with stroke
recurrence, major adverse cardiovascular events (MACE), and mortality in patients with
CE and whether this association is affected by AF.
Methods: We enrolled patients with CE who underwent ABI measurements during
hospitalization. Recurrent stroke was defined based on newly developed neurologic
symptoms with relevant lesions 7 days after the index stroke. MACE comprised stroke
recurrence, myocardial infarction, or death.
Results: Of 775 patients, 427 (55.1%) were AF patients and 348 (44.9%) were non-AF
patients. Patients were followed up for a median of 33.6 (IQR, 18.0–51.6) months.
In total, 194 (25.0%) patients experienced MACE, including 77 (9.9%) patients with
stroke recurrence and 101 (13.0%) patients with mortality, during the study period.
Multivariable Cox regression analysis showed that an ABI <0.9 was independently
associated with MACE (AF patients: hazard ratio [HR] = 2.327, 95% confidence interval
[CI]= 1.371–3.949, non-AF patients: HR= 3.116, 95% CI= 1.465–6.629) and mortality
(AF patients: HR = 2.659, 95% CI = 1.483–4.767, non-AF patients: HR = 3.645,
95% CI = 1.623–8.187). Stroke recurrence was independently associated with an ABI
<0.9 in AF patients (HR = 3.559, 95% CI = 1.570–8.066), but not in non-AF patients
(HR = 1.186, 95% CI = 0.156–8.989).
Conclusions: We found that a low ABI is associated with stroke recurrence, MACE, and
mortality in patients with CE. In particular, the association between ABI and recurrent
stroke is only present in AF patients. A low ABI may be a useful prognostic marker in
patients with CE, especially in AF patients.
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INTRODUCTION
Globally, stroke occurs in over 12 million people each year and is
the third leading cause of death and disability (1). The majority
of strokes are ischemic strokes and are caused by atherosclerosis,
small vessel occlusion, or cardioembolism. Among these causes,
cardioembolic stroke (CE) accounts for 25–40% of cerebral
infarctions (2). Furthermore, CE is associated with a 3-fold
case fatality rate and relatively high recurrence rates of 22.0–
35.5% compared to other types of ischemic stroke (2, 3). Atrial
fibrillation (AF) is the most common cause of CE and the
presence of AF has been reported to increase the risk of stroke
recurrence by 54% (4). In addition, although stroke mortality
has been reduced by 36% over the past 30 years, the disability-
adjusted life-years were ranked second following ischemic heart
disease in patients aged 50 years and older (1, 5). A high stroke
burden in the elderly may be linked to an increased incidence
of risk factors, including AF, and resulting cardiovascular events
(6). Oral anticoagulant therapy with a vitamin K antagonist
or a direct oral anticoagulant can reduce the relative risk of
stroke recurrence by 60–70% (7, 8). However, many patients still
experience recurrent stroke and poor cardiovascular outcomes
despite taking oral anticoagulants (9). Therefore, it is crucial
to identify high-risk populations among CE patients to reduce
further the risk of stroke recurrence.
Peripheral artery disease (PAD) is characterized by abnormal
narrowing of arteries that reduces blood flow to the limbs. PAD
is typically diagnosed if the ankle-brachial index (ABI) is below
0.9 (10). We previously reported that an ABI <0.9 is a predictive
factor of initial stroke severity (11) and an independent predictor
of poor functional outcome at 3 months in patients with acute
stroke (12). Large population-based studies showed that PAD
is associated with the incidence of AF (13–15). Meta-analysis
demonstrated that presence of PAD was associated with a 31%
increase in risk for incident AF (16). However, outcome of
acute ischemic stroke patients who have both PAD and AF is
largely unknown.
Therefore, the purpose of this study is to reveal the impact of
a low ABI on the outcome in acute ischemic stroke patients with
CE. We sought to determine whether a low ABI is associated
with stroke recurrence, major adverse cardiovascular events
(MACE), and all-cause mortality in patients with CE. We also




A single-center, hospital-based, retrospective observational study
was conducted using prospectively collected stroke registry data.
Between January 1, 2007, and June 30, 2013, 3,821 consecutive
patients with acute cerebral infarction or transient ischemic
attack (TIA) within 7 days of symptom onset were admitted to
the study hospital and registered. During admission, all patients
were thoroughly investigated for demographic data, medical
history, vascular risk factors, and clinical manifestations. All
patients underwent brain computed tomography (CT) and/or
magnetic resonance imaging (MRI), 12-lead electrocardiography,
and standard blood tests. Acute cerebral infarction was defined
as the sudden onset of acute neurological deficits of presumed
vascular etiology lasting 24 h or evidence of acute infarction
on brain CT or MRI. TIA was diagnosed when a patient
showed transient (<24 h) neurologic dysfunction of vascular
origin and did not have acute lesions on CT or MRI. Patients
were treated using standard treatment protocols based on the
guidelines for acute ischemic stroke. Stroke classifications were
determined during weekly conferences. Based on the consensus
of three stroke neurologists, stroke subtypes were classified
according to the Trial of ORG 10172 in Acute Stroke Treatment
(TOAST) classification (17). Briefly, large artery atherosclerosis
is defined when there is significant (≥50%) stenosis of the
large artery relevant to the acute infarction. Cardioembolism
is defined when there is at least one potential cardiac source
of embolism, which is defined in the TOAST classification. A
patient with a small vessel occlusion should have one of the
classic clinical lacunar syndromes and a relevant subcortical
hemispheric or brain stem lesion with a diameter smaller
than 1.5 cm. Stroke of other determined etiology includes
patients with a rare cause of stroke, such as non-atherosclerotic
vasculopathy, hypercoagulable state, and hematologic disorder.
Stroke of undetermined etiology is defined when the mechanism
of stroke cannot be determined and is further subdivided into
undetermined etiology because of multiple causes identified,
undetermined etiology attributable to negative evaluation despite
extensive examinations, and undetermined etiology attributable
to incomplete evaluation (18).
From the 3,821 patients, we excluded patients with stroke
subtypes other than CE, including TIA (n = 52), large artery
atherosclerosis (n= 762), small vessel occlusion (n= 329), stroke
of other determined cause (n= 89), stroke of undetermined cause
(n = 1,499; two or more causes [n = 682], negative evaluation
[n = 806], and incomplete evaluation [n = 11]), and those in
whom ABI measurements were not performed (n = 315). After
exclusion, 775 patients with CE were finally enrolled in this study
(Supplementary Table 1). Patients with CE were divided into
two groups based on the presence of AF (Figure 1).
This study was approved by the Institutional Review Board
of Severance Hospital, Yonsei University Health System. The
requirement for informed consent was waived because of the
retrospective nature of the analysis (4-2019-1196).
Clinical Variables
Upon admission, we collected data on baseline characteristics,
including sex, age, and neurological deficits [National Institutes
of Health Stroke Scale (NIHSS) score], presence of risk
factors, and laboratory data (glucose, low-density lipoprotein,
and total cholesterol). Hypertension was defined as a resting
systolic blood pressure of ≥140 mmHg or diastolic blood
pressure of ≥90 mmHg after repeated measurements during
hospitalization or through the current use of antihypertensive
medication. Diabetes mellitus was defined as a fasting plasma
glucose level of ≥7 mmol/L or through the current use of
an oral hypoglycemic agent or insulin. Hypercholesterolemia
was diagnosed in patients taking lipid-lowering agents after a
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FIGURE 1 | Flowchart of participants according to inclusion and exclusion criteria. ABI, ankle-brachial index.
diagnosis of hypercholesterolemia or in those with low-density
lipoprotein cholesterol levels ≥4.1 mmol/L or total cholesterol
levels ≥6.2 mmol/L. Current smoking was defined as having
smoked a cigarette within 1 year prior to admission. Congestive
heart failure was determined based on history of heart failure
diagnosis, treatment with loop diuretics, and ejection fraction
of ≤35% on echocardiography. Coronary artery disease was
diagnosed when a patient had a history of coronary artery disease
(acute myocardial infarction, unstable angina, coronary artery
bypass graft, or percutaneous coronary artery stent/angioplasty)
or the presence of significant stenosis (≥50%) in any of the three
main coronary arteries on multislice CT coronary angiography
upon admission. The CHA2DS2-VASc scores were calculated for
all patients, with one point assigned to patients with a history of
congestive heart failure, hypertension, aged 65–74 years, diabetes
mellitus, female sex, vascular diseases (coronary artery disease
or atheroma in the aortic arch/ascending/descending aorta), and
two points for patients aged ≥75 years and those with a history
of stroke or TIA. The CHA2DS2-VASc scores were also divided
into three groups (0: low risk, 1: intermediate risk, ≥2: high risk)
based on a previous study (19).
ABI Measurement
The ABI was measured in the supine position using an automatic
device (VP-1000; Colin Co., Ltd., Komaki, Japan), which has
been validated previously (20). The device automatically and
simultaneously measures four-limb blood pressure using the
oscillometric method. The ABI was calculated as the ratio of the
ankle systolic blood pressure divided by the higher systolic blood
pressure of the arms. After obtaining bilateral ABI values, the
lower value was used for analysis. A low ABI was defined as ABI
<0.9. Patients with low ABI were defined as when the ABI <0.9
is present in one or more sides of the ankle (11, 12). The mean
values of the systolic and diastolic blood pressures in both ankles
were also used for analysis.
Follow-Up and Outcome Measures
After discharge, each patient was followed up regularly at
3 months, 1 year, and then yearly. At each follow-up visit,
medical information including occurrence of any cardiovascular
events, newly detected vascular risk factors, and re-admission
to another hospital was obtained via face-to-face interviews
with neurologists or through clinical research associates in the
outpatient clinic. When the patients missed a scheduled visit,
we obtained the information from the patients or their proxy
through a telephone interview with a structured questionnaire.
Short-term functional outcomes at 3 months were determined
using a structured interview with the modified Rankin Scale
(mRS). A poor short-term outcome was defined as an mRS
≥3. MACE were defined as any stroke recurrence, myocardial
infarction occurrence, or death. Stroke recurrence was defined
as newly developed neurologic symptoms with relevant lesions
on brain CT and/or MRI 7 days after an index stroke or
hospital discharge. Loss of follow-up occurred in 110 (14.2%)
of 775 patients. When the patients were admitted to another
hospital due to stroke recurrence or occurrence of myocardial
infarction, we attempted to obtain medical records and imaging
results. If this was not possible, stroke recurrence was determined
by the investigators using telephone interview. Deaths among
participants from January 1, 2007, to December 31, 2013, were
confirmed by matching the information in the death records and
identification numbers assigned to participants at birth (18). We
obtained data for the date and cause of death from the death
certificates from the Korean National Statistical Office.
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Statistical Analysis
SPSS (version 26, SPSS, Chicago, IL, USA) and SAS (version
9.4, SAS Inc., Cary, NC, USA) were used for statistical analysis.
The statistical significance of intergroup differences was assessed
using the χ2 or Fisher’s exact test for categorical variables
and the independent two-sample t-test or Mann-Whitney U-
test for continuous variables. Data are expressed as mean ±
standard deviation or median [interquartile ranges (IQRs)]
for continuous variables, and numbers (%) for categorical
variables. The correlation between an ABI <0.9 and CHA2DS2-
VASc scores was determined using the Spearman rank test.
Mediation analysis was performed to evaluate whether a low
ABI mediates the association between AF and outcomes.
Survival curves were generated according to the Kaplan-Meier
method and compared using the log-rank test. Log-log plots
were performed to verify the proportional hazards assumption
of the strata (Supplementary Figure 1). Multivariable Cox
proportional hazard regression was performed after adjusting
for the NIHSS score at admission, CHA2DS2-VASc variables
(age, sex, hypertension, diabetesmellitus, congestive heart failure,
vascular disease, and previous TIA/infarction), and additional
cardiovascular risk factors (hypercholesterolemia and smoking)
to investigate the independent association of an ABI <0.9
with unfavorable outcomes. All p-values were two-tailed, and
differences were considered significant at p < 0.05.
RESULTS
Patient Demographics and Clinical
Characteristics
Of the 3,821 patients, 775 (20.3%) were eligible and classified as
CE. The mean age of the study patients was 65.5 ± 12.7 years,
and 333 (43.0%) were women. We divided CE patients into 427
(55.1%) patients with AF and 348 (44.9%) patients without AF.
Compared to non-AF patients, AF patients were older, more
likely to have hypertension and congestive heart failure, and less
likely to be current smokers (all p < 0.05). Patients with a low
ABI were also more frequent in the group of AF patients (10.3
vs. 4.3%, p = 0.002). The initial NIHSS score was higher in AF
patients (5.0 [2.0, 13.0] vs. 2.0 [1.0, 5.0], p < 0.001). CHA2DS2-
VASc scores were higher in AF patients than in non-AF patients
(3.4 ± 1.7 vs. 2.7 ± 1.7, p < 0.001). A poor short-term outcome
(mRS≥3) at 3 months was more frequent in AF patients (24.7 vs.
15.2%, p= 0.001; Supplementary Table 2).
Comparison According to Presence of AF
and Low ABI
Of the 427 patients with AF, the mean age was 69.5 ± 10.5
years, and 184 (43.1%) AF patients were female (Table 1). When
compared with AF patients with an ABI ≥0.9, those with an
ABI <0.9 were less likely to be female and more likely to have
a previous TIA/infarction and lower ankle blood pressure (all
p < 0.05). Poor short-term outcomes at 3 months were more
frequent in AF patients with an ABI <0.9 than in those with
an ABI ≥0.9 (46.5 vs. 22.2%, p < 0.001). Among AF patients,
CHA2DS2-VASc scores were higher in patients with an ABI <0.9
than in those with an ABI ≥0.9 (Spearman rank test; p < 0.05;
Figure 2A). The mean age of the 348 non-AF patients was 60.5
± 13.5 years, and 149 (42.8%) of them were female. Compared to
non-AF patients with an ABI ≥0.9, those with an ABI <0.9 were
more likely to have diabetes mellitus, congestive heart failure,
and lower ankle blood pressure (all p < 0.05). Among non-AF
patients, CHA2DS2-VASc scores were higher in patients with an
ABI <0.9 than in those with an ABI ≥0.9 (Spearman rank test; p
< 0.05; Figure 2B).
Association Between Low ABI and
Long-Term Outcomes
Patients were followed up for a median of 33.6 (IQR, 18.0–51.6)
months. A total of 194 (25.0%) patients had MACE, including
77 (9.9%) with stroke recurrence and 101 (13.0%) with all-cause
mortality, during the study period. Stroke recurrence rates were
higher in patients with AF than in those without AF (13.6 vs.
5.5%, p < 0.001) and higher in patients with an ABI <0.9 than
in those with an ABI ≥0.9 (18.6 vs. 9.2%, p= 0.02).
Kaplan-Meier curves showed that an ABI <0.9 was associated
with stroke recurrence, MACE occurrence, and all-cause
mortality in patients with CE (log-rank test, all p < 0.05;
Supplementary Figure 2). In particular, an ABI <0.9 was
associated with stroke recurrence in patients with AF (log-rank
test, p = 0.015; Figure 3A). However, an ABI <0.9 was not
associated with stroke recurrence in non-AF patients (log-rank
test, p = 0.655; Figure 3B). MACE and all-cause mortality were
associated with an ABI <0.9 in both AF and non-AF patients
(log-rank test, all p < 0.05). Analysis of four groups according
to the presence of AF and an ABI <0.9 showed that stroke
recurrence was highest in patients who had both AF (+) and
an ABI <0.9. Occurrence of MACE and mortality was higher in
patients with AF (+) and ABI <0.9 and patients with AF (–) and
an ABI <0.9 compared to those with AF (+) and an ABI ≥0.9
and those with AF (–) and an ABI ≥0.9 (log-rank test, all p <
0.001; Figure 4).
Multivariable Cox regression analysis after adjusting for
the initial NIHSS score, smoking status, hypercholesterolemia,
and CHA2DS2-VASc variables showed that an ABI <0.9 was
independently associated with MACE occurrence [AF patients:
hazard ratio (HR) 2.327, 95% confidence interval (CI) 1.371–
3.949, non-AF patients: HR 3.116, 95% CI 1.465–6.629] and all-
cause mortality (AF patients: HR 2.659, 95% CI 1.483–4.767,
non-AF patients: HR 3.645, 95% CI 1.623–8.187). In particular,
an ABI<0.9 was independently associated with stroke recurrence
in AF patients (HR 3.559, 95% CI 1.570–8.066). However, an
ABI <0.9 was not associated with stroke recurrence in non-AF
patients (HR 1.186, 95% CI 0.156–8.989) (Table 2).
DISCUSSION
We demonstrated that PAD, defined as an ABI <0.9, was
independently associated with long-term MACE occurrence and
all-cause mortality in patients with CE. In particular, in AF
patients, an ABI <0.9 was independently associated with an
increased risk of stroke recurrence, long-termMACE occurrence,
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TABLE 1 | Patient demographics and clinical characteristics according to AF and an ABI <0.9.
AF (+) and ABI
<0.9 (n = 44)
AF (+) and ABI
≥0.9 (n = 383)
p-value AF (–) and ABI
<0.9 (n = 15)
AF (–) and ABI
≥0.9 (n = 333)
p-value
Age, y 71.4 ± 14.4 69.3 ± 9.9 0.362 65.7 ± 12.8 60.3 ± 13.5 0.132
Sex (female) 18 (40.9) 166 (43.3) <0.001 6 (40.0) 143 (42.9) 0.822
NIHSS score at admission 9.5 [4.0, 19.0] 5.0 [2.0, 13.0] 0.758 4.0 [2.0, 5.0] 2.0 [1.0, 5.0] 0.195
mRS ≥3 at 3 months 20 (46.5) 84 (22.2) <0.001 4 (26.7) 47 (14.6) 0.259
Recurrent stroke 10 (22.7) 48 (12.5) 0.062 1 (6.7) 18 (5.4) 0.577
CHA2DS2-VASc score
0 3 (6.8) 13 (3.4) 0.195 1 (6.7) 25 (7.5) 0.159
1 2 (4.5) 46 (12.0) 0 (0.0) 64 (19.2)
≥2 39 (88.6) 324 (84.6) 14 (93.3) 244 (73.3)
Risk factors
Hypertension 33 (75.0) 276 (72.1) 0.680 12 (80.0) 210 (63.1) 0.182
Diabetes mellitus 14 (31.8) 93 (24.3) 0.275 8 (53.3) 77 (23.1) 0.013
Hypercholesterolemia 10 (22.7) 69 (18.0) 0.446 4 (26.7) 68 (20.4) 0.523
Current smoking 4 (9.1) 55 (14.4) 0.337 5 (33.3) 85 (25.5) 0.548
Congestive heart failure 10 (22.7) 49 (12.8) 0.071 3 (20.0) 17 (5.1) 0.047
Vascular disease 22 (50.0) 190 (49.6) 0.961 11 (73.3) 178 (53.5) 0.131
Previous TIA/infarction 11 (25.0) 49 (12.8) 0.027 4 (26.7) 41 (12.3) 0.114
Laboratory findings
Glucose, mg/dL 155.1 ± 79.7 133.7 ± 46.9 0.086 210.8 ± 192.0 137.5 ± 58.5 0.162
LDL, mg/dL 105.3 ± 35.4 104.6 ± 33.7 0.888 110.5 ± 44.0 114.9 ± 40.6 0.689
Total cholesterol, mg/dL 169.8 ± 39.5 168.9 ± 37.1 0.907 172.9 ± 49.5 182.4 ± 44.4 0.423
Ankle blood pressure
SBP, mmHg 114.9 ± 22.2 159.1 ± 26.9 <0.001 121.8 ± 26.2 161.7 ± 28.8 <0.001
DBP, mmHg 60.4 ± 15.7 77.8 ± 13.2 <0.001 69.7 ± 15.1 79.6 ± 14.4 0.010
ABI* 0.72 ± 0.15 1.10 ± 0.09 <0.001 0.79 ± 0.12 1.11 ± 0.08 <0.001
Data are expressed as mean ± standard deviation, median [interquartile ranges], or numbers (%). *After obtaining bilateral ABI values, the lower value was used for the analysis.
Peripheral artery disease was not considered in the CHA2DS2-VASc score. ABI, ankle-brachial index; AF, atrial fibrillation; DBP, diastolic blood pressure; LDL, low-density lipoprotein;
mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; SBP, systolic blood pressure; TIA, transient ischemic attack.
FIGURE 2 | Association between the CHA2DS2-VASc score and an ABI <0.9 in (A) AF and (B) non-AF patients. ABI, ankle-brachial index; AF, atrial fibrillation.
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FIGURE 3 | Kaplan-Meier survival analysis. (A) Recurrent stroke in AF patients with an ABI <0.9. (B) Recurrent stroke in non-AF patients with an ABI <0.9. ABI,
ankle-brachial index; AF, atrial fibrillation.
and all-cause mortality after adjusting for CHA2DS2-VASc
variables. Meanwhile, an ABI <0.9 was associated with MACE
and all-cause mortality in non-AF patients but not with stroke
recurrence. These findings suggest that PAD is associated with
poor long-term prognosis in patients with CE and that PAD is
only associated with recurrent stroke in patients with AF.
A lowABI is an establishedmarker of systemic atherosclerosis,
which is associated with increased mortality in the elderly
population (21) and stroke patients (22). Other studies found that
PAD, defined as an ABI <0.9, is related to increased severity of
the initial stroke (11), a higher risk of recurrence (23), and poor
outcomes in patients with all ischemic stroke (12). Consistent
with these reports, our findings showed that after adjusting for
CHA2DS2-VASc variables and cardiovascular risk factors, an ABI
<0.9 is independently associated with a worse stroke prognosis.
Previous studies evaluated the prognostic effect of PAD in all
stroke or non-cardioembolic stroke patients (24, 25). However,
the prognostic value of PAD in CE is not fully understood.
This may be associated with concerns regarding the accuracy
of ABI measurements in patients with CE. To address these
concerns, the reliability of ABI measurements during AF was
studied by comparing ABI values measured during AF and
sinus rhythm from the same patients. The study concluded
that the ABI is accurate for the diagnosis of PAD also during
AF (26). Another concern is the interaction between AF and
PAD. Both are strong prognostic factors after index stroke
(27–29). We found that an ABI <0.9 is more prevalent in
AF patients than in non-AF patients and the presence of an
ABI <0.9 is associated with a high CHA2DS2-VASc score. We
also found that a low ABI mediates the association between
AF and outcome (Supplementary Table 3). To overcome this
interaction, multivariate analysis was conducted after adjusting
for the CHA2DS2-VASc score. We demonstrated that a low
ABI is an independent prognostic indicator for poor functional
outcome, MACE, and mortality.
Among stroke subtypes, the stroke recurrence rate was higher
in patients with CE [3]. AF is the most frequent cardiac condition
associated with CE and is amajor determinant of recurrent stroke
(30). We showed that patients with AF are more likely to have
stroke recurrence. Furthermore, our study demonstrated that
patients with AF and an ABI <0.9 more frequently experienced
recurrent stroke than patients with AF and an ABI ≥0.9. In
contrast, an ABI <0.9 was not associated with stroke recurrence
in non-AF patients. Therefore, the association between PAD and
stroke recurrence is only valid in patients with AF, showing that
PAD is differentially associated with stroke recurrence in patients
with CE.
Several hypotheses can explain the effect of AF on stroke
outcome in patients with PAD. First, the CHA2DS2-VASc
score is known to be associated with systemic atherosclerosis,
which increases the risk of stroke recurrence (23, 31–33).
Therefore, high CHA2DS2-VASc scores in PAD patients with
AF may lead to an increased risk of recurrence. Second, only
in patients with both AF and PAD there was a significant
association with stroke recurrence after adjusting for CHA2DS2-
VASc variables. A previous study reported that a direct link
and a dose-effect response relationship exist between PAD
and AF (16). Therefore, the overlap between AF and PAD
may have a synergistic effect and promote stroke recurrence
(34, 35). Third, AF is a hemodynamic disorder, which causes
endothelial damage by abnormal flow shear forces (36). We
found that AF directly or indirectly affects poor functional
outcome, MACE, and mortality through PAD in the mediation
analysis. However, stroke recurrence was not mediated through
PAD (defined by ABI <0.9) (Supplementary Table 3), while
AF was associated with stroke recurrence through PAD
(defined by continuous ABI) (Supplementary Table 4). These
finding suggest that there may be a mediating effect of
PAD between AF and stroke recurrence. Thus, atherosclerosis
exacerbated by AF may increase the risk of adverse outcomes,
including recurrent stroke (37). Finally, AF and PAD can
exist as bystanders. Stroke recurrence rates may be higher
because each is a significant risk factor for recurrent stroke
(23, 27). However, further prospective studies are needed to
assess the causal relationship between AF with PAD and
stroke recurrence.
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FIGURE 4 | Kaplan-Meier survival analysis for (A) recurrent stroke, (B) major adverse cardiovascular events, and (C) all-cause mortality according to AF and an ABI
<0.9. ABI, ankle-brachial index; AF, atrial fibrillation.
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TABLE 2 | Multivariate Cox proportional hazards regression analysis.
Stroke recurrence MACE Mortality
HRa (95% CI) HRb (95% CI) HRa (95% CI) HRb (95% CI) HRa (95% CI) HRb (95% CI)
NIHSS score at admission 1.033 (0.998–1.070) 1.032 (0.996–1.069) 1.049 (1.027–1.072)c 1.048 (1.025–1.072)c 1.056 (1.031–1.081) 1.053 (1.027–1.079)c
Hypercholesterolemia 0.939 (0.523–1.686) 0.925 (0.510–1.679) 0.744 (0.502–1.102) 0.793 (0.533–1.179) 0.690 (0.442–1.077) 0.756 (0.482–1.186)
Current smoking 1.157 (0.615–2.174) 1.326 (0.660–2.666) 1.276 (0.873–1.864) 1.584 (1.041–2.409)c 1.304 (0.861–1.977) 1.755 (1.103–2.794)c
CHA2DS2-VASc score
0 Ref Ref Ref
1 1.775 (0.198–15.917) 3.129 (0.710–13.782) 5.460 (0.709–42.025)
≥2 4.989 (0.690–36.047) 6.200 (1.534–25.056)c 10.110 (1.410–72.492)c
CHA2DS2-VASc score component
Age 65–74 1.316 (0.725–2.389) 1.652 (1.114–2.448)c 2.051 (1.280–3.287)c
Age ≥75 1.994 (1.053–3.776)c 2.728 (1.810–4.112)c 4.344 (2.708–6.969)c
Sex (female) 1.352 (0.811–2.255) 1.185 (0.859–1.635) 1.162 (0.806–1.676)
Hypertension 0.931 (0.544–1.591) 1.270 (0.892–1.808) 1.257 (0.847–1.866)
Diabetes mellitus 1.426 (0.869–2.338) 1.312 (0.959–1.796) 1.296 (0.906–1.854)
Congestive heart failure 0.753 (0.362–1.565) 1.310 (0.875–1.963) 1.597 (1.042–2.448)c
Vascular disease 1.300 (0.812–2.079) 0.926 (0.691–1.241) 0.845 (0.609–1.173)
Previous TIA/infarction 1.253 (0.683–2.300) 0.873 (0.575–1.326) 0.874 (0.552–1.382)
Groups
AF (–) and ABI ≥0.9 Ref Ref Ref Ref Ref Ref
AF (–) and ABI <0.9 1.186 (0.156–8.989) 1.006 (0.131–7.705) 3.116 (1.465–6.629)c 2.660 (1.237–5.718)c 3.645 (1.623–8.187)c 3.100 (1.362–7.056)c
AF (+) and ABI ≥0.9 1.743 (0.991–3.063) 1.780 (0.990–3.199) 1.305 (0.926–1.840) 1.121 (0.782–1.607) 1.357 (0.924–1.993) 1.061 (0.709–1.589)
AF (+) and ABI <0.9 3.559 (1.570–8.066)c 3.212 (1.342–7.684)c 2.327 (1.371–3.949)c 1.798 (1.032–3.133)c 2.659 (1.483–4.767)c 1.783 (0.967–3.287)
Data were derived from the Cox proportional hazards regression analysis. Peripheral artery disease was not considered in the CHA2DS2-VASc score. ABI, ankle-brachial index; AF, atrial
fibrillation; CI, confidence interval; HR, hazard ratio; MACE, major adverse cardiovascular event; NIHSS, National Institutes of Health Stroke Scale; TIA, transient ischemic attack.
aAdjusted for NIHSS score at admission, hypercholesterolemia, current smoking, and CHA2DS2-VASc score.
bAdjusted for NIHSS score at admission, hypercholesterolemia, current smoking, age 65–74, age ≥75, sex, hypertension, diabetes mellitus, congestive heart failure, vascular disease,
and previous TIA/infarction.
cp < 0.05.
This study has several limitations. First, the definition
of PAD was not based on medical history and radiological
study findings. It is known that medical histories obtained
from PAD patients are often inaccurate, and subclinical
PAD is prevalent. In this study, radiological examinations to
detect atherosclerosis in the extremities were not routinely
conducted. However, the ABI is recommended for use in
clinical practice and research according to guidelines from the
American College of Cardiology/American Heart Association
(ACC/AHA) (10). Second, this study was a retrospective
cohort study, and there was a follow-up loss of 14.2%.
This may have influenced the statistical analyses. Third,
our findings may not be generalizable to other populations
or ethnicities because our study population was limited to
Korean patients.
CONCLUSION
This study showed that PAD is associated with poor long-term
outcomes, including stroke recurrence, MACE, and all-cause
mortality in patients with CE. In particular, the association
between PAD and recurrent stroke is only observed in
patients with AF. Therefore, an ABI <0.9 may be a useful
prognostic marker in patients with CE, especially in those
with AF.
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